Global

SHERIDAN, WYOMING - November 25, 2025 - In radiology, the most transformative AI of the coming decade may not be the algorithms that make headlines, but the ones that quietly shave minutes off every case, reduce clicks, and keep worklists flowing smoothly for overburdened imaging teams. That is the vision outlined by Shez Partovi, MD, Chief Innovation Officer and Chief Business Leader Enterprise Informatics at Philips, who argues that the future of AI in radiology is the AI you barely notice - deeply embedded into workflows rather than bolted on as yet another standalone tool.

From "Will it help?" to "How fast can you implement it?"

SHERIDAN, WYOMING - November 25, 2025 - Nestlé is piloting a novel, patented cocoa processing technique that uses up to 30% more of each cocoa fruit, aiming to boost farmer yields, reduce waste and create new product opportunities for the global food processing and ingredients industry. By turning traditionally underused parts of the cocoa pod into chocolate flakes, the company is testing a more resource-efficient model for chocolate production in the face of climate pressure on cocoa supply.

Turning more of each cocoa pod into value
Conventional chocolate production relies almost exclusively on cocoa beans, leaving pulp, placenta and husk largely underutilized. Nestlé's R&D organization has reframed that paradigm by developing a method that leverages all of the edible material inside the pod, not just the beans. In doing so, it directly addresses both raw material efficiency and the economic potential of each harvested fruit.

SHERIDAN, WYOMING - November 25, 2025 - Nestlé and its research partners have created a new cocoa core collection that captures more than 95% of the crop's global genetic diversity, laying a strategic foundation for a more resilient cocoa supply chain serving chocolate manufacturers and food producers worldwide. By consolidating genetic resources into a curated set of 96 varieties, the project aims to accelerate breeding of climate-resilient, higher-yield and quality-enhanced cocoa tailored to the needs of the global food and beverage industry.

A 'Noah's Ark' for cocoa genetics
The heart of the initiative is a core collection that condenses thousands of potential trees into a representative set of 96 cocoa varieties. This enables researchers and breeders to work on a manageable but comprehensive portfolio of genetic material, cutting time and complexity from pre-commercial research.

SHERIDAN, WYOMING - November 13, 2025 - Dentsply Sirona and Rapid Shape have jointly advanced digital denture manufacturing by validating the Lucitone Digital Print Denture System across Rapid Shape's D50+, D90+ and PRO 20 3D printers. The collaboration expands access to high-strength printable denture materials and fully automated workflows, helping dental laboratories scale production as technician shortages and patient demand intensify globally.

A Major Expansion of Validated Digital Denture Workflows

SHERIDAN, WYOMING - November 13, 2025 - Dentsply Sirona celebrated two decades of its Global Clinical Case Contest (GCCC), honoring dental students who demonstrated exceptional restorative dentistry skills and a growing mastery of digital workflows. The anniversary event highlighted how the company continues to invest in early-career clinicians, raising global standards in esthetic and functional dentistry through hands-on education, mentorship and modern restorative technologies.

A Milestone Year for an International Training Platform

SHERIDAN, WYOMING - November 13, 2025 - Amgen has released detailed Phase 3 data that could reshape how health systems approach primary prevention of cardiovascular events. The VESALIUS-CV results show that adding Repatha to standard lipid-lowering therapy significantly reduces major adverse cardiovascular events (MACE) in high-risk adults with no prior history of heart attack or stroke-an evidence base that could expand eligibility criteria, support more assertive LDL-C management strategies, and influence payer and provider adoption models across the U.S. and abroad.

SHERIDAN, WYOMING - November 13, 2025 - Amgen's landmark VESALIUS-CV trial is redefining where PCSK9 inhibition fits in cardiovascular care, showing that Repatha can significantly cut major events even in high-risk adults who have never had a heart attack or stroke. For hospital systems, cardiology networks, and payers, the findings strengthen the case for treating low-density lipoprotein cholesterol (LDL-C) much more aggressively and much earlier in the patient journey.

Here is your fully rewritten, SEO-savvy B2B article following all rules of the updated prompt (no meta, no keywords, no watermarking, no duplication, 500-650 words, bolded H5-style subheads only, one verbatim quote used exactly as provided).

Amgen's Repatha Data Signals a Potential Shift Toward Earlier Preventive Cardiology

SHERIDAN, WYOMING - November 13, 2025 - New Phase III data from Amgen's VESALIUS-CV study are accelerating industry conversations around earlier preventive intervention in cardiology, with the company positioning Repatha as the first PCSK9 inhibitor to demonstrate event reduction in high-risk adults without a prior heart attack or stroke. For hospital systems, cardiology practices, and value-based care organizations, the findings add fresh momentum to a class of therapies long debated for their adoption challenges.